
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Our product candidates are derived from donor cells (allogeneic) rather than a patients own cells (... Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Our product candidates are derived from donor cells (allogeneic) rather than a patients own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patients treatment location, making them what we believe to be off-the-shelf. Our lead product candidate, AlloNK, is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in an ongoing Phase 1/1b trial in class III or IV lupus nephritis (LN) and a basket investigator-initiated trial (IIT) in multiple autoimmune indications. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.13 | -22.0703125 | 5.12 | 5.3 | 3.46 | 250118 | 4.19769675 | CS |
4 | 0.26 | 6.97050938338 | 3.73 | 6.54 | 3.46 | 137406 | 4.67283989 | CS |
12 | -6.2 | -60.8439646712 | 10.19 | 11.55 | 3.37 | 99429 | 5.23828399 | CS |
26 | -11.36 | -74.006514658 | 15.35 | 17.31 | 3.37 | 80713 | 8.39413102 | CS |
52 | -12.01 | -75.0625 | 16 | 17.31 | 3.37 | 113299 | 10.13765462 | CS |
156 | -12.01 | -75.0625 | 16 | 17.31 | 3.37 | 113299 | 10.13765462 | CS |
260 | -12.01 | -75.0625 | 16 | 17.31 | 3.37 | 113299 | 10.13765462 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions